Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
completion around
Principal Investigator
by Wanxing Chai-Ho, MD (ucla)
Headshot of Wanxing Chai-Ho
Wanxing Chai-Ho

Description

Summary

This purpose of this study is to establish proof of concept of tebapivat in participants with LR-MDS in Phase 2a and to evaluate the effect of tebapivat on transfusion independence (TI) in participants with LR-MDS in phase 2b.

Official Title

A Phase 2a/2b, Open-label, Proof of Concept (Phase 2a) and Open-label (Phase 2b), Multicenter, Efficacy, and Safety Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes

Keywords

Myelodysplastic Syndromes, Anemia, Lower-Risk Myelodysplastic Syndromes, Preleukemia, Syndrome, Tebapivat

Eligibility

Locations

  • David Geffen School of Medicine at UCLA accepting new patients
    Los Angeles California 90024 United States
  • Innovative Clinical Research Institute Whittier completed
    Lakewood California 90805 United States
  • Emad Ibrahim, MD, Inc. accepting new patients
    Redlands California 92373 United States

Lead Scientist at University of California Health

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Agios Pharmaceuticals, Inc.
ID
NCT05490446
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 82 study participants
Last Updated